and CD8 (cytotoxic-suppressor, 24%) T cell subpopulations were present (CD4/CD8 ratio of 2 .6) .
The CD4 subset contained a predominance of CD45R+ cells (78%), as is normally seen early in life (16) control MLCs failed to demonstrate any suppressor cell activity . Strikingly, the addition of exogenous IL-2 to these in vitro assays completely restored the proliferative responses in a dose-dependent fashion (Table I) . In addition, the patient's PBMC proliferated and could be propagated in vitro using immobi- tion of cell surface receptors necessary for T cell proliferation, such as the CD25 and CD71 antigens, was assessed (Fig. 1) . In the absence of exogenous IL-2, patient's cells expressed the CD25 and CD71 antigens, although they were slightly diminished in comparison to control cells (data not shown was added to PHA-stimulated cultures, normal amounts of the CD25 and CD71 antigens (Fig. 1) , as well as MHC class II molecules (data not shown), were expressed. The normal expression of the CD25 antigen implies that protein kinase C (PKC) activation is not defective, as these events are linked (17) . In addition, the patient's PBMC demonstrated a comparable rise in intracellular calcium levels after crosslinking of surface-bound OKT3 as that seen with control PBMC (data not shown) .
To determine the nature ofthe IL-2 production deficiency, Northern blot analysis was performed (Fig . 2) . After cellular activation, control PBMC demonstrated a large increase in RNAs for IL-2, IL-2 receptor, cytotoxic serine protease-B, IFN -'1', and GM-CSR The patient's cells produced no IL-2 transcripts under any circumstances, although both IL-2 receptor and cytotoxic serine protease B transcripts were readily induced. Induction of IFN-y and GM-CSF transcripts was diminished in patient's cells compared with normal controls, although a weak signal was detectable. Other lymphokine transcripts including IL-3, IL-4, and IL-6 were also present (data not shown) . In vitro expanded patient's lymphocytes derived from short-term (10-d) cultures using immobilized OKT3 and exogenous IL-2 were also analyzed. As with freshly isolated PBMC, in vitro expanded patient's cells produced no IL-2 transcripts after stimulation. However, as shown in Fig. 3 , IFN-y and GM-CSF transcripts were now readily detectable, indicating that transcription from these loci was FIGURE 2. Northern blot analysis of freshly isolated PBMC following activation for 6 h with (1) no stimulus, (2) 5 ng/ml PMA and 5 lug/ml PHA, or (3) 5 ng/ml PMA and 0.3 pM ionomycin. 10 Wg of total RNA was used for each filter. cDNA probes were labeled using a-[32 PJdCTP Autoradiography was for 72 h at -70°C for all probes except actin which was for 24 h at -70°C. augmented in the presence of IL-2 . Southern blot analysis using a full-length IL-2 cDNA probe revealed no differences in restriction patterns between patient's DNA and placental DNA using a variety of enzymes (Bam HI, Bgl II, Eco RI, Hind III, Pvu II, or Xba I; data not shown). All hybridizing fragments were as predicted from the known organization of the human IL-2 gene locus (18) .
Discussion
Although a variety of additional growth factors exist that augment T cell proliferation, the dominant mechanism for T cell growth is via the interaction of IL-2 with the IL-2 receptor. This autocrine pathway is critical for the generation and maintenance of functional immune responses. This patient suffers from a congenital immunodeficiency which appears to be the consequence of an inability ofhis circulating T cells to produce IL-2. Interestingly, of the various functional assays, the MLC response was relatively spared . This may be explained by back-production of IL-2 by the irradiated stimulator cells in response to the patient's cells, allowing the patient's cells to proliferate. The partial response to PMA and ionomycin may be due to production ofother lymphokines such as IL-3, IL-4, IL-6, or GM-CSF with subsequent proliferation of responsive T and/or non-T cell populations. However, longterm in vitro growth of T cells in response to OKT3 could only be stimulated by exogenous IL-2, suggesting that the proliferative response to PMA and ionomycin might involve predominantly nonT cells.
The defect appears selective to IL-2, in that cell surface receptors and other lymphokines can be detected, although at diminished levels compared with control cells. This may be in part a consequence of absent IL-2 production, as levels increase with the addition of exogenous IL-2 . It is well established that the IL-2 receptor and IFN--y expression are augmented by IL-2 (19) , and it appears that GM-CSF transcription may also be upregulated by IL-2. Although it remains possible that deficiencies in transmembrane signaling may be involved in the IL-2 deficiency, this seems unlikely as the patient's PBMC can mobilize intracellular calcium, and can apparently activate PKC, as evidenced by the expression of the CD25 antigen . Moreover, stimuli that bypass the cell surface (PMA and ionomycin) fail to induce IL-2 transcription .
The absence of IL-2 production may involve alterations in the IL-2 gene or in the mechanisms regulating its transcription . We found no gross structural alterations in the IL-2 gene locus, although we cannot rule out a point mutation or small deletion . Alternatively, the defect in IL-2 production may relate to an abnormality of one of the nuclear trans-acting proteins that bind to target sequences upstream of the IL-2 gene and regulate IL-2 transcription (20) . The only T cell-specific DNA binding protein implicated in regulating IL-2 production is NFAT1 (21) . It is tempting to speculate that the patient's defect may reside in NFAT1 or another yet unidentified transcriptional activator. Lack of such a factor might also contribute to the diminution of the other T cell-produced lymphokines (IFN-'Y and GM-CSF) .
This child's genetic disorder provides important insights into T cell development which require further analysis. Specifically, this child developed and maintained a normal circulating T cell pool in the absence of detectable peripheral IL-2 production. Although IL-2 has been implicated in intrathymic T cell development (2, 3), this child's immunodeficiency disorder suggests that prethymic and intrathymic T cell development may occur in the setting ofan IL-2 production defect, and reciprocally, that IL-2 deficiency does not in and ofitself result in T lymphopenia . Alternatively, it may suggest that intrathymic IL-2 production may be regulated by distinct mechanisms from those that regulate IL-2 production in peripheral T cells. This child has provided important in vivo information as to the morphologic and functional consequences of peripheral IL-2 deficiency. His illness confirms the central role of IL-2 in the immune response, but suggests that data implicating IL-2 in intrathymic development must either be reconsidered, or that alternative pathways of T cell development may also exist.
Summary
We have characterized a child with a severe combined immunodeficiency disease syndrome with increased numbers, but a normal distribution, of CD3 + T cells. This patient's immunological defect appears to be attributable to a selective deficiency in T cell production of IL-2, which may reflect a subtle abnormality in the IL-2 gene locus or a defect in a regulatory factor necessary for IL-2 transcription . The increased numbers of phenotypically normal T cells in this patient suggest that alternative pathways ofT cell development exist in man or that IL-2 production intraand extrathymically is controlled via distinct regulatory mechanisms.
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